Table 4.
Demographic characteristics and concomitant comorbidities prevalence in patients with and without neurocognitive symptoms at follow-up visits
| Neurocognitive symptoms—yes (n = 7) | Neurocognitive symptoms—no (n = 93) | P value | |
|---|---|---|---|
| Age, years | 62 (52-71) | 61 (53-70) | .77 |
| Male gender, n (%) | 3 (43%) | 53 (57%) | .69 |
| BMI at follow-up, kg/m2 | 27.3 (24-32) | 27.1 (23-30) | .53 |
| Overweight/obese, n (%) | 5 (70%) | 69 (74%) | >.99 |
| Hypertension, n (%) | 3 (43%) | 36 (39%) | .43 |
| Cardiovascular disease, n (%) | 1 (14%) | 8 (8.6%) | .49 |
| Diabetes mellitus, n (%) | 1 (14%) | 7 (7.5%) | .45 |
| Active neoplasia, n (%) | 0 (0%) | 3 (3.2%) | >.99 |
| NIMV, n. (%) | 1 (14%) | 28 (30%) | .67 |
| CRP at admission, mg/dL | 77.7 (35-151) | 74 (33-139) | .86 |
| LDH at admission, U/L | 426 (305-545) | 444 (311-564) | .81 |
| N/L ratio at admission | 4.9 (3.5-7.1) | 5.2 (3.8-8) | .54 |
| Albumin at admission, g/L | 31.5 (29-37) | 31.8 (28-36) | .85 |
| CRP at follow-up, mg/dL | (n = 5) 4.2 (2.7-7.6) | (n = 72) 4 (2.2-7) | .75 |
| LDH at follow-up, U/L | (n = 3) 158 (131-225) | (n = 37) 145 (112-218) | .38 |
| N/L ratio at follow-up | 1.78 (1.3-2.1) | 1.76 (1.2-2.4) | .82 |
Abbreviations: BMI, body mass index; CRP, C-reactive protein; LDH, lactate dehydrogenase; NIMV, noninvasive mechanical ventilation; N/L neutrophil to lymphocyte.